Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?

BACKGROUND AND PURPOSE Distant metastases are the dominant mode of failure after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC). The primary study objective was to evaluate if the maximum standardized uptake value (SUV(max)) on pre-treatment FDG-PET/CT predicted clinical outcomes. Secondary objectives were to correlate 3-month post-SBRT SUV(max) and change in SUV(max) with outcomes. MATERIALS AND METHODS Consecutive patients with medically inoperable early-stage NSCLC and an FDG-PET/CT scan before (n=82) and 3 months after (n=62) SBRT. RESULTS Median follow up was 2 years. On univariate analysis baseline SUV(max) predicted for distant failure (p=0.0096), relapse free survival (RFS) (p=0.037) and local failure (p=0.044). On multivariate analysis baseline SUV(max) predicted for RFS (p=0.037). Baseline SUV(max) of above 5 was the most statistically significant cut off point for predicting distant failure (p=0.0002). Baseline SUV(max) ≥4.75 (median) was correlated with a higher risk of distant failure (p=0.012) and poorer RFS (p=0.04). Patients with a post-SBRT SUV(max) ≥2 and a reduction of <2.55 had a significantly higher rate of distant failure. CONCLUSIONS Pre-SBRT SUV(max) on FDG-PET/CT correlated most strongly with distant failure. A cut off of ≥5 was the most significant. Post-SBRT SUV(max) ≥2 and a reduction of <2.55 were associated with a higher risk of distant failure.

[1]  P. Saintigny,et al.  [A controlled study of postoperative radiotherapy for patients with completely resected non small cell lung carcinoma]. , 2000, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[2]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer , 2007 .

[3]  T. Araki,et al.  Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. , 2012, European journal of radiology.

[4]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[5]  Toshio Ohashi,et al.  The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Alfons G H Kessels,et al.  Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  John Cho,et al.  Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. , 2012, International journal of radiation oncology, biology, physics.

[9]  Hiroki Shirato,et al.  Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? , 2011, International journal of radiation oncology, biology, physics.

[10]  P. Blitzer,et al.  Medically Inoperable Lung Carcinoma: The Role of Radiation Therapy. , 1996, Seminars in radiation oncology.

[11]  Zhongxing Liao,et al.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  M. Graham,et al.  Radiation therapy alone for stage I non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[13]  C. Reddy,et al.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[14]  K. Togashi,et al.  Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  R. Gralla,et al.  Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. , 2009, Lung cancer.

[16]  D. Lee,et al.  Determination of the prognostic value of [18F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer , 2002, Nuclear medicine communications.

[17]  D. Yan,et al.  Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  C. Dooms,et al.  Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. , 2004, Chest.

[19]  M. Gail,et al.  Prognostic factors in patients with resected stage I non‐small cell lung cancer. A report from the Lung Cancer Study Group , 1984, Cancer.

[20]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[21]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[22]  V. Rusch,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. , 2007, The Journal of thoracic and cardiovascular surgery.

[23]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Sonke,et al.  Time Interval Between Staging FDG Positron Emission Tomography (PET) and Initiation of Stereotactic Lung Radiotherapy (SBRT) Impacts the Risk of Recurrence and Metastasis in Non-small Cell Lung Cancer (NSCLC) , 2010 .

[25]  F. Gao,et al.  Prognostic Value of Preoperative Positron Emission Tomography in Resected Stage I Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  R. Arriagada,et al.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma , 1999, Cancer.

[27]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .